Organon & Co. (OGN) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2025
Loading P/E history...
OGN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Organon & Co. (OGN) trades at a price-to-earnings ratio of 18.5x, with a stock price of $13.31 and trailing twelve-month earnings per share of $0.72.
The current P/E is 212% above its 5-year average of 5.9x. Over the past five years, OGN's P/E has ranged from a low of 3.6x to a high of 10.1x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, OGN trades at a 17% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, OGN trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our OGN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
OGN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $151B | 19.5 | - | -4% | |
| $358B | 85.5 | - | -1% | |
| $41B | 19.1Lowest | 2.26 | +13% | |
| $42B | 30.0 | - | +183% | |
| $2B | 25.3 | - | +419%Best | |
| $92B | 29.2 | 0.75Best | +15% | |
| $44B | 28.7 | - | +87% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
OGN Historical P/E Data (2021–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $7.17 | $0.71 | 10.1x | +71% |
| FY2025 Q3 | $10.68 | $1.92 | 5.6x | -6% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $9.68 | $2.69 | 3.6x | -39% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $14.89 | $2.88 | 5.2x | -13% |
| FY2024 Q4 | $14.92 | $3.33 | 4.5x | -24% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $19.13 | $5.04 | 3.8x | -36% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $20.70 | $3.89 | 5.3x | -10% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $18.80 | $4.09 | 4.6x | -22% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $14.42 | $4.00 | 3.6x | -39% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $17.36 | $2.29 | 7.6x | +28% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $20.81 | $2.95 | 7.1x | +19% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $23.52 | $2.92 | 8.1x | +36% |
Average P/E for displayed period: 5.9x
See OGN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OGN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OGN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOGN — Frequently Asked Questions
Quick answers to the most common questions about buying OGN stock.
Is OGN stock overvalued or undervalued?
OGN trades at 18.5x P/E, above its 5-year average of 5.9x. The 100th percentile ranking indicates a premium to historical valuation.
How does OGN's valuation compare to peers?
Organon & Co. P/E of 18.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is OGN's PEG ratio?
OGN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2025.